@article{TAU22650,
author = {Avi Patel and Sarah Cohen and Ravan Moret and Grace Maresh and Glenda C. Gobe and Li Li},
title = {Patient-derived xenograft models to optimize kidney cancer therapies},
journal = {Translational Andrology and Urology},
volume = {8},
number = {Suppl 2},
year = {2018},
keywords = {},
abstract = {Renal cell carcinoma (RCC) is the most common solid neoplasm of the adult kidney and has a high potential for developing metastatic spread. Approximately 25–30% of RCC patients have metastatic disease at presentation, and 30–40% of patients develop metastases after the initial diagnosis. Advanced renal cancer is a deadly and difficult-to-treat cancer. The 5-year survival rate of patients with metastatic disease is less than 10%, partly because RCC metastases become resistant to current therapies. Pre-clinical models may help to identify the optimum therapeutic options for individual patients. Here we reviewed various mouse xenograft methods for RCC treatment screening especially patient-derived orthotopic xenograft models. Advantages and disadvantaged of some of the models are also discussed.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/22650}
}